Molecular prognostic factors in locally irresectable rectal cancer treated preoperatively by chemo-radiotherapy

Anticancer Res. 2004 Mar-Apr;24(2C):1217-21.

Abstract

Purpose: The aim of this study was to determine the relationship between survival and value of molecular markers in the primary tumour in a group of patients with irresectable rectal cancer, treated with preoperative chemo-radiotherapy.

Materials and methods: Immunohistochemistry for p53, p21, bcl-2 and Ki-67 was performed on pre-treatment biopsy specimens of 34 patients with irresectable rectal cancer. Preoperative treatment consisted of pelvic irradiation of 45-56 Gy, combined with 5FU and leucovorin (350/20 mg/m2 x 5 d; in weeks 1 and 5 during radiotherapy). The median follow-up was 38 months. Endpoints were pathological T-stage and survival after surgery.

Results: Expression of p21 correlated significantly with survival (p=0.005). Survival and p21 expression also correlated significantly, when adjusted for tumour response (p=0.005, RR=4.8 (1.6-14.7)).

Conclusion: Expression of p21 predicts a worse survival in irresectable rectal cancer treated with preoperative chemo-radiotherapy. No relationship was found between tumour response in chemo-radiotherapy and p53, bcl-2 or Ki-67.

MeSH terms

  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins / biosynthesis*
  • Cyclins / genetics
  • Gene Expression
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen / biosynthesis*
  • Ki-67 Antigen / genetics
  • Neoadjuvant Therapy
  • Preoperative Care
  • Prognosis
  • Proto-Oncogene Proteins c-bcl-2 / biosynthesis*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • Rectal Neoplasms / genetics*
  • Rectal Neoplasms / metabolism
  • Rectal Neoplasms / therapy*
  • Tumor Suppressor Protein p53 / biosynthesis*
  • Tumor Suppressor Protein p53 / genetics

Substances

  • CDKN1A protein, human
  • Cyclin-Dependent Kinase Inhibitor p21
  • Cyclins
  • Ki-67 Antigen
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Protein p53